Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung fluid immune cells may predict immunotherapy success

NCT ID NCT07331701

Knowledge-focused Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will examine immune cells found in fluid from the lungs of 60 people with advanced lung cancer. Researchers want to see if these cells can help predict how well standard cancer treatments work. Participants will have a bronchoscopy as part of their regular care, and the fluid collected will be analyzed for different types of immune cells.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better ways to predict which lung cancer patients will respond to immunotherapy, improving treatment decisions.
What could go wrong
This is a small, early observational study, not a treatment trial. It may not find a clear link, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population comprises adult patients evaluated at SMG-SNU Boramae Medical Center in Seoul, Republic of Korea. Participants are drawn from routine clinical practice and include patients undergoing clinically indicated bronchoscopy as part of the diagnostic evaluation or management of suspected or confirmed stage IV lung cancer. All clinical assessments, treatments, and follow-up are performed according to standard-of-care practice based on current clinical guidelines, and no additional diagnostic or therapeutic procedures are introduced solely for research purposes.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 19 years or older * Patients with suspected or histologically confirmed stage IV lung cancer based on clinical and radiologic findings * Scheduled to undergo clinically indicated bronchoscopy with bronchoalveolar lavage as part of routine clinical care * Able and willing to provide written informed consent Exclusion Criteria: * Receipt of treatment for acute lower respiratory tract infection (including pneumonia or fungal infection) within 4 weeks prior to bronchoscopy * History of solid organ transplantation or hematopoietic stem cell transplantation * Current use of systemic immunosuppressive therapy * Current or planned use of biologic immunomodulatory agents * Known autoimmune disease requiring systemic immunosuppressive treatment * Pregnant women * Patients with recurrent stage IV lung cancer after prior definitive therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung carcinoma lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung neoplasms Tumor immune microenvironment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • SMG-SNU Boramae Medical Center

    Seoul, Dongjak-gu, 07061, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.